Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.87 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
94 95 Next >
Investors should take notice of NYSE:MRK—it offers a great deal for the fundamentals it presents.
Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued. 
Via Chartmill
7 Mutual Funds That Will Outperform in Any Market
While we’d all love to think we’re market geniuses, we could use the active management of outperforming mutual funds. 
Via InvestorPlace
3 Pharma Stocks to Sell in February Before They Crash and Burn
The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn. 
Via InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Beyond The Numbers: 8 Analysts Discuss Merck & Co Stock
Via Benzinga
Merck & Company Inc. (NYSE: MRK) Records 52-Week High Thursday Morning
Via Investor Brand Network
Merck & Co's Earnings: A Preview
Via Benzinga
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Merck Stock Rocketed Nearly 5% Skyward Today
The company reported healthy sales growth and proffered encouraging guidance to boot. 
Via The Motley Fool
How Is The Market Feeling About Merck & Co?
Via Benzinga
Why the quality investor may take a look at MERCK & CO. INC. (NYSE:MRK).
Why MERCK & CO. INC. (NYSE:MRK) Deserves Consideration as a Quality Investment. 
Via Chartmill
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a... 
Via Benzinga
Exposures COVID-19
Merck (MRK) Q4 2023 Earnings Call Transcript
MRK earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?
Wall Street rebounds after Fed meeting with all major indices up, buoyed by earnings & dovish expectations. Probability for March cut at 41%, speculators increase bets for future cuts. Jobless claims... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Merck Posts Surprise Quarterly Profit Against An Expected Loss, Oncology And Vaccines Drive Growth
Merck reports fourth quarter 2023 sales of $14.63 billion, a 6% YoY increase, beating estimates. Explore oncology, vaccines, and EPS outlook for 2024. 
Via Benzinga
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February. 
Via Benzinga
Merck Reports A Surprise Profit As Keytruda Sales Continue On Their Warpath
Analysts expected an 11-cent per-share loss from Merck in the fourth quarter. But the company came out ahead. 
Via Investor's Business Daily
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
From Merck & Co., Inc.
Via Business Wire
Earnings Scheduled For February 1, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... 
Via Benzinga
Powell Dubious On March Cut, Markets Slide
Markets pulled back from their steady trading levels today once Fed Chair Jerome Powell, speaking at his press conference following the latest Fed meeting 
Via Talk Markets
Topics Economy
Exposures Interest Rates
IBM, Verizon, Merck stocks lead Dow to new highs
The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance 
Via MarketBeat
Topics Stocks
Exposures US Equities
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings
Merck stock has gained 20% since Nov. 28; a technical signal suggests the rally isn't over. Keytruda approvals also drive optimism. 
Via Benzinga
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments. 
Via Benzinga
Hope for Kidney Cancer Patients, Merck's Keytruda Cuts Risk Of Death By 38% Following Surgery
Results from Merck's Phase 3 KEYNOTE-564 trial. Keytruda, an adjuvant treatment for renal cell carcinoma, shows a 38% improvement in overall survival at 57.2 months. 
Via Benzinga
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
These companies can perform well through this bull run and beyond. 
Via The Motley Fool
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Merck's Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows
Merck's Keytruda results in treating high-risk urothelial carcinoma. Discover statistically significant improvements in disease-free survival at ASCO GU Cancers Symposium 2024. 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
94 95 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.